Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $13.4 million.

  • Spero Therapeutics' Operating Expenses fell 5833.7% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.4 million, marking a year-over-year decrease of 1877.48%. This contributed to the annual value of $121.3 million for FY2024, which is 4743.38% up from last year.
  • Per Spero Therapeutics' latest filing, its Operating Expenses stood at $13.4 million for Q3 2025, which was down 5833.7% from $16.6 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Operating Expenses peaked at $36.8 million during Q4 2024, and registered a low of $13.4 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Expenses was $23.7 million (2021), whereas its average is $24.0 million.
  • As far as peak fluctuations go, Spero Therapeutics' Operating Expenses surged by 9802.75% in 2023, and later crashed by 5833.7% in 2025.
  • Over the past 5 years, Spero Therapeutics' Operating Expenses (Quarter) stood at $30.2 million in 2021, then fell by 28.86% to $21.5 million in 2022, then grew by 6.85% to $23.0 million in 2023, then skyrocketed by 59.93% to $36.8 million in 2024, then tumbled by 63.67% to $13.4 million in 2025.
  • Its Operating Expenses was $13.4 million in Q3 2025, compared to $16.6 million in Q2 2025 and $20.6 million in Q1 2025.